|Home||» Products||» Anticancer Injectables||» Mitoxantrone Injection|
It is a synthetic antineoplastic anthracenedione for intravenous use. Although its mechanism of action is not fully elucidated, it is a DNA - reactive agent. It has a cytocidal effect on with proliferating and non proliferating cultured small cells suggesting lock of cell cycle specifically.
|Composition :||Each ml contains:
Mitoxantrone ------------------------2 mg
|Indications :||It is used in the treatment of metastatic breast cancer and of non-Hodgkinâs lymphomas, alone or with other agents. It may also be given to treat adult acute myeloid leukemia. Mitoxantrone has also been used in patients with hormone-refractory prostate cancer, liver cancer, and ovarian cancer. In addition, mitoxantrone is used in the management of secondary progressive or relapsing multiple sclerosis, to reduce neurological disability or the frequency of relapses.
|Contraindications :||Mitoxantrone for injection is contraindicated in patients who have demonstrated prior hypersensitivity to it.
|Adverse Effects :||Serious adverse reactions including anaphylaxis and allergic reactions, neuropathy,pulmonary toxicities and hepatotoxicities can occur..|
|Dosage :||In the treatment of breast cancer, prostate cancer, liver cancer, and lymphomas, a dose equivalent to mitoxantrone 14 mg/m2 is given initially and then repeated every 3 weeks. It is diluted to at least 50 ml in sodium
chloride 0.9% or glucose 5% and injected over at least 3 minutes into a freely-running intravenous infusion of
either. Subsequent doses may be adjusted according to the degree of Myelosuppression produced. Initial dosage
may need to be reduced to 12 mg/m2 in debilitated patients or those who have had previous Hemotherapy.
|Precautions:||Special Populations in Carcinogenesis, Mutagenesis, Impairment of Fertility, Hepatic Impairment, Pregnancy, Nursing Mothers, Pediatric Use, Geriatric Use, Multiple Sclerosis, Hormone-Refractory Prostate Cancer, Acute Nonlymphocytic Leukemia.|